Jump to main content
Jump to site search

Issue 10, 2018
Previous Article Next Article

Simultaneous determination of rifampicin, isoniazid, pyrazinamide and ethambutol in fixed-dose combination antituberculosis pharmaceutical formulations: a review

Author affiliations

Abstract

According to the World Health Organization, rifampicin, isoniazid, pyrazinamide and ethambutol hydrochloride are the first-line drugs used to treat tuberculosis – an infectious disease caused by Mycobacterium tuberculosis. Since 2010, tuberculosis has been treated with a fixed-dose combination containing the four drugs in only one tablet, called 4-FDC, which has simplified the treatment, minimized prescription errors and increased patients' adherence to their treatment regime. Within this context, the present review aims to show the evolution of different analytical methods that have been applied to simultaneous 4-FDC content determination in pharmaceutical formulations, such as high performance liquid chromatography, ultrahigh performance liquid chromatography, thin layer chromatography and capillary electrophoresis as separation techniques and molecular spectroscopic techniques associated with chemometric approaches, such as UV, Raman, Fourier transform infrared and near infrared.

Graphical abstract: Simultaneous determination of rifampicin, isoniazid, pyrazinamide and ethambutol in fixed-dose combination antituberculosis pharmaceutical formulations: a review

Back to tab navigation

Article information


Submitted
20 Nov 2017
Accepted
08 Feb 2018
First published
12 Feb 2018

Anal. Methods, 2018,10, 1103-1116
Article type
Critical Review

Simultaneous determination of rifampicin, isoniazid, pyrazinamide and ethambutol in fixed-dose combination antituberculosis pharmaceutical formulations: a review

M. A. L. Oliveira, P. R. Chellini and T. L. Amorim, Anal. Methods, 2018, 10, 1103
DOI: 10.1039/C7AY02686B

Social activity

Search articles by author

Spotlight

Advertisements